GSK Acquires Syndivia's Prostate Cancer ADC
GSK has acquired the rights to Syndivia's preclinical antibody drug conjugate (ADC) for prostate cancer treatment, despite already having its own ADC in development for the same condition.
This move demonstrates GSK's confidence in the modality, fuelling the industry's interest in ADCs as a promising anti-tumour treatment.
The gold standard of business intelligence.
GSK's acquisition is valued at £268m, highlighting the company's commitment to investing in innovative cancer treatments.
Author's summary: GSK buys Syndivia's prostate cancer ADC for £268m.